Skip to main navigation

About
Research & Development
Pipeline
Investors
Careers

Press Releases

Press Releases

Year

November 9, 2022

Revolution Medicines to Participate in Upcoming Investor Conferences

November 7, 2022

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress

November 1, 2022

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

September 22, 2022

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

September 1, 2022

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

August 31, 2022

Revolution Medicines to Participate in Upcoming Investor Conferences

August 9, 2022

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

July 28, 2022

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

July 22, 2022

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

July 19, 2022

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 21 - 30 of 113

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2023 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063
CCPA Notice | Privacy Policy

Search Investor Relations